For NSCLC, recommendations comprised larotrectinib/entrectinib (unconventional SLC28A3::NTRK2 gene fusion), capmatinib (MET amplification, GCN: 16.7), afatinib (RBPMS::NRG1 gene fusion), and dabrafinib/trametinib in the case of a BRAF p.Val600Glu, and a non-V600E BRAF mutated tumor, respectively. The gene discussed is SLC28A3; the disease is non-small cell lung carcinoma.